CMPS6:30 AMCompass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable ProfileTrial Results • Phase 3compasspathways.com
CMPS6:30 AMCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)compasspathways.com
CMPS6:30 AMCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)compasspathways.com
CMPS6:30 AMCompass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026compasspathways.com
CMPS6:30 AMCompass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026compasspathways.com
CMPS6:30 AMCompass Pathways Announces First Quarter 2026 Financial Results and Business Highlightscompasspathways.com
CMPS6:30 AMCompass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026compasspathways.com
CMPS6:25 AMCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)compasspathways.com
CMPS10:37 AMCompass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Vouchercompasspathways.com
CMPS6:30 AMCompass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatmentscompasspathways.com
CMPS6:30 AMCompass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026compasspathways.com
CMPS4:12 PMCompass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatmentscompasspathways.com
CMPS6:30 AMCompass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Trainingcompasspathways.com